Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study

Hamel, Remi K.; Chen, Ling; O’Connell, Cailin; Mann, Caroline

doi:10.7759/cureus.34169

Cited by 5 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[19][20][21][22][23][24][25][26][27][28][29][30] Dr. SKS hair booster serum has already demonstrated its safety and efficacy in treating AGA in both males and females with a 95% patient selfassessment score and in treating FPHL in patients with polycystic ovary syndrome. 10,11 In the current study, we discovered that intradermal administration of Dr. SKS hair booster serum reduced hair loss, improved hair regrowth, and increased hair density in patients with persistent TE following COVID-19 recovery.…”

Section: Discussionmentioning

confidence: 65%

See 1 more Smart Citation

Efficacy of Dr. SKS hair booster serum for the treatment of hair loss in COVID-19 induced persistent telogen effluvium

Khare

2024

Int J Res Med Sci

View full text Add to dashboard Cite

Background: Excessive hair shedding occurs in patients with coronavirus disease 2019 induced telogen effluvium. Dr. SKS hair booster serum has demonstrated encouraging benefits in different types of alopecia in previous studies. We sought to evaluate the efficacy of Dr. SKS hair booster serum for the treatment of COVID-19 induced persistent TE. Methods: A total of 500 patients aged 18 to 60 years who had recovered from reverse transcription-polymerase chain reaction proven COVID-19 infection but experienced sustained hair fall even after 6 months were included in the study. One millilitre of Dr. SKS hair booster serum injection was administered intradermally in scalp per session. Efficacy and safety outcomes were evaluated at baseline, 3 and 6 months after the treatment. Results: Approximately half of the patients demonstrated excellent improvement in expert panel global photographic assessment at 3 months (vertex area; 43.6% and frontal area; 46%) that was increased at 6 months (vertex area; 48% and frontal area; 50%). Each patient's clinical condition improved. All patients were satisfied with the results in terms of mean total hair growth satisfaction scale score of five aspects at 3 and 6 months treatment. Conclusions: Intradermal injection of Dr. SKS hair booster serum proves to be effective treatment for hair loss in COVID-19-induced persistent TE.

show abstract

Section: Discussionmentioning

confidence: 65%

“…[4][5][6][7] Considering unavailability of standard protocol and lack of definitive treatment in TE patients following COVID-19 recovery and promising results of Dr. SKS hair booster serum in various types of alopecia we aimed to evaluate the efficacy of Dr. SKS hair booster serum for the treatment of COVID-19 induced persistent TE. [8][9][10][11]…”

mentioning

confidence: 99%

Efficacy of Dr. SKS hair booster serum for the treatment of hair loss in COVID-19 induced persistent telogen effluvium

Khare

2024

Int J Res Med Sci

View full text Add to dashboard Cite

show abstract

“…However, no reduction in pruritus or perifollicular hyperkeratosis was observed. The side effects of treatment include vivid dreams, insomnia, headaches, thirst, and xerostomia, and these should be taken into consideration before treatment [95].…”

Section: Naltrexonementioning

confidence: 99%

The Frontal Fibrosing Alopecia Treatment Dilemma

Krzesłowska,

Woźniacka

2024

JCM

View full text Add to dashboard Cite

Frontal fibrosing alopecia (FFA) is a type of cicatricial alopecia predominantly observed in postmenopausal women, with the incidence rising since its initial description in 1994. The exact etiopathogenesis of the disease has not been completely elucidated. FFA is characterized by an inflammatory process affecting the hair follicles of the fronto-temporal hairline, leading to its gradual recession. Eyebrows, particularly the lateral parts, may also be affected. Early diagnosis and an implementation of effective therapy to limit the inflammatory process are crucial in halting disease progression. Various treatment possibilities have been reported, including anti-inflammatory and immunosuppressive agents, as well as 5-alpha-reductase inhibitors, retinoids, and antimalarial agents. The use of phototherapy and surgical procedures has also been described. However, most available data have been obtained retrospectively, frequently consisting of descriptions of case reports or small case series, and not from randomized controlled trials. In addition, the etiopathogenesis of FFA remains unclear and its course unpredictable, occasionally being linked with spontaneous stabilization. Hence, no precise guidelines exist regarding treatment modalities. Therefore, the aims of this study were to provide a comprehensive review of the efficacy of existing therapeutic modalities for FFA and to highlight novel therapeutic options.

show abstract

Low-Dose Naltrexone Use in Biopsy-Proven Lichen Planus of the Nails

Bray,

Morrison

2024

JAMA Dermatol

View full text Add to dashboard Cite

ImportanceNail lichen planus has the potential to cause permanent destruction of the nail unit and remains challenging to treat. Studies suggest that low-dose naltrexone is a safe and potentially effective treatment for other dermatologic conditions, including lichen planopilaris.ObjectiveTo assess the effectiveness of low-dose naltrexone in treating nail lichen planus.Design, Setting, and ParticipantsThis case series evaluates 7 adult patients with biopsy-proven nail lichen planus who were treated with low-dose naltrexone (3 mg per day) at the University of Miami dermatologic clinics from November 2022 to December 2023. The data were analyzed in March 2024. Patients were treated for at least 2 months and had in-person follow-up evaluation while receiving treatment.Main Outcomes and MeasuresThe main outcome was posttreatment clinical nail lichen planus severity index, which was scored as clear, mild, moderate, or severe. Patients were evaluated for oral and cutaneous disease during the course of treatment. Tolerance and adverse events were noted.ResultsA total of 7 patients (mean [range] age, 60 [38-77] years; 3 female individuals) were included. All but 1 patient had been previously treated and did not respond to at least 1 prior treatment (median [range], 2.5 [0-4.0] treatments). Treatment duration ranged from 2 to 11 months. Clinical response was observed in 4 of 7 patients, with an overall 35% reduction in nail lichen planus severity index. Two patients with severe disease achieved a reduction to mild severity. None of the patients had to discontinue low-dose naltrexone due to adverse events, and no adverse events were reported.Conclusions and RelevanceThe results of this study suggest that low-dose naltrexone may be a therapeutic approach for treating nail lichen planus. Further controlled studies are warranted to better understand its clinical efficacy and safety profile in treating nail lichen planus.

show abstract

Oral Low-Dose Naltrexone in the Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris: An Uncontrolled Open-Label Prospective Study

Cited by 5 publications

References 23 publications

Efficacy of Dr. SKS hair booster serum for the treatment of hair loss in COVID-19 induced persistent telogen effluvium

Efficacy of Dr. SKS hair booster serum for the treatment of hair loss in COVID-19 induced persistent telogen effluvium

The Frontal Fibrosing Alopecia Treatment Dilemma

Low-Dose Naltrexone Use in Biopsy-Proven Lichen Planus of the Nails

Contact Info

Product

Resources

About